Last updated 29 March, 2020
Cancer Research UK, OHSU Knight Cancer Institute and the Canary Center at Stanford, have been closely monitoring developments relating to the coronavirus (COVID-19) outbreak and reviewing guidance from government bodies. After careful consideration, we have made the decision to convert the Early Detection of Cancer Conference 2020 to a virtual conference, instead of the scheduled in-person conference on October 6-8 in London, UK.
With the number of attendees, including those travelling internationally, and given that many of you work with vulnerable communities, we agreed that safeguarding your health and safety, and the health and safety of those you work with, is our priority. With global restrictions on international travel continuing to grow, it would not be possible to hold the event in its current format without impacting on the quality of the sessions.
We understand this is disappointing news, and in light of the work invested in building the 2020 in-person program, our plan is to host the virtual conference over the same scheduled dates of October 6-8 2020.
Please review our cancellation policy below, and if you have any questions please email email@example.com
Important cancellation information
All registrants will automatically be refunded their full refund of their ticket, and we will notify you when the virtual conference tickets are available.
Cancer Research UK are not liable for any travel or accommodation costs relating to attendee bookings.
Poster and proffered talks
Once the new conference has been confirmed, we ask you to resubmit your abstract for consideration.
ABOUT THE CONFERENCE
Cancer Research UK, OHSU Knight Cancer Institute and the Canary Center at Stanford, present the Early Detection of Cancer Conference series. The annual Conference brings together experts in early detection from multiple disciplines to share ground breaking research and progress in the field.
The Conference is part of a long-term commitment to invest in early detection research, to understand the biology behind early stage cancers, find new detection and screening methods, and enhance uptake and accuracy of screening.